Mercia Ventures

Invizius is a medical technology company focused on improving outcomes in extracorporeal blood treatments. It develops H-Guard, a hemocompatible coating designed to prevent foreign body reactions in the blood at the point of contact with medical devices used in dialysis, cardiopulmonary bypass, and extracorporeal membrane oxygenation. By reducing inflammatory and thrombotic complications associated with long-term dialysis and other extracorporeal circuits, Invizius aims to lower cardiovascular risk and improve patient safety during kidney replacement therapies and related procedures. Based in Edinburgh, United Kingdom, the company was established in 2018 and pursues additional applications in inflammatory and kidney-related conditions through its technology platform.